Clinical Trial
NCT05537220 Recruiting, Active
Oral N-acetylcysteine for Retinitis Pigmentosa (NAC Attack)
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa
Disease
Disease type
Hereditary retinal disease
Retinitis Pigmentosa
Patient type
Adult
Children
Inclusion / Exclusion
Funding
private
Members involved
Others investigators

Pr Katarina Stingl
Representative
Germany
Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader

Pr Carel HOYNG
Representative
Netherlands
Genetic Diagnostics (TWG6), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Pr Camiel BOON
Representative
Netherlands
Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
ERN EYE member investigating site
HCP : Principal investigators

Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany
Adress
Department für Augenheilkunde Tübingen Forschungsinstitut für Augenheilkunde Elfriede-Aulhorn-Str. 7
72076 Tübingen
Germany

University Hospital Graz, Department of Neuro-Ophthalmology, Graz, Austria
Adress
Auenbruggerplatz 4
8036 Graz
Austria

Radboud university medical center, Nijmegen, Netherlands
Adress
Geert Grooteplein Zuid 10
6525 GA Nijmegen
Netherlands

Amsterdam University Medical Center / Leiden University Medical Center
Adress
Albinusdreef 2
2333 ZA Leiden
Netherlands